Sitemap
March 25, 2017 Articles
Filter by Available Specialty
- ‘Major need’ exists for more effective mucosal melanoma treatments
- Anti–PD-1/PD-L1 therapy ‘rapidly becoming’ standard of care for Merkel cell carcinoma
- Baseline factors predict survival benefit from BRAF/MEK inhibitor combination
- Challenges remain in determining appropriate sequence of immunotherapy, BRAF/MEK inhibition
- Gene mutation burden linked to primary site of melanoma
- Hedgehog inhibitors ‘game changers’ for advanced basal cell carcinoma
- JAK inhibitors demonstrated efficacy comparable to TNF inhibitors
- Molecular testing requires additional validation before ready for prime time in melanoma
- New research center will accelerate the development of new antibiotics
- PUBLICATION EXCLUSIVE: Which DRCR.net protocol has had the biggest impact on your practice?
- Speaker: Rheumatologists must be prepared for immune-mediated diseases
- Stryker introduces new cage sizes of 3D-printed spinal implants
- Trials begun to evaluate empagliflozin for treatment of HF
- VIDEO: Decision to undergo lymph node dissection remains ‘complicated’
- VIDEO: New immune targets may improve advanced melanoma outcomes
- VIDEO: Rheumatic diseases attributed to altered relationship with microbial world